The survival outcomes of patients with lung cancer are substantially related to EGFR mutations (such as L858R and exon 19 deletion or insertion) or overexpressed ERBB family members that promote EGFR activity by increasing dimerization or ATP affinities [87,88]. Here, EGFR is linked to lung cancer.